Rheumatoid Arthritis with Orencia Trial Toward Sjogren's syndrome endocrinopathy (ROSE Trial)
Phase 2
Recruiting
- Conditions
- rheumatoid arthritis complicated by sjogren's syndrome
- Registration Number
- JPRN-UMIN000005724
- Lead Sponsor
- Division of Clinical Immunology, Major of Advanced Biochemical Applications, Graduate School of Comprehensive Human Science,University of Tsukuba Takayuki Sumida
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
1)contraindicated patients 2)patients over 75 years of age 3)Patients with a total leukocyte count of 3000/mm3 or less, 4)pregnant women or lactating mothers, women with child-bearing potential and patients wishing to become pregnant during this study 5)patients under 20 years of age 6)patients who had received any drugs for treatment of Sjogren's syndrome, including cevimeline hydrochloride hydrate, anetholtrithion, and pilocarpine hydrochloride within 4 weeks prior to the study treatment 7) patients with any concurrent serious disorders of the liver, kidney or hematopoietic organs 8) anti centromere antibody positive 9)Patients who are inadequate by investigator's decision.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method